LETTERS TO THE EDITOR
Vitamin A supplementation in developing countries EDITOR,-I was frustrated by the recent annotation on vitamin A supplementation in developing countries.' My main complaint is the inability of Dr Filteau and Professor Tomkins to endorse vitamin A supplementation among children living in poverty.
The authors are concerned that 15 mg (50 000 IU) of supplemental retinol given at about 1-5, 2-5, and 3-5 months has been associated with an 11% excess incidence of bulging fontanelle among young infants.2 However, the infants in this study received more frequent doses of vitamin A than is likely necessary for clinical benefit3 4; there was a higher chance of having unnecessary side effects among those treated. A similar trial, using a single dose of 50 000 IU retinol among neonates, failed to demonstrate any significant adverse effects.5 Furthermore, Filteau and Tomkins incorrectly state that the bulging fontanelle represents vitamin A 'toxicity' when, in fact, this phenomenon is transient, and has no proved adverse effect on a baby ( We regret that Dr Joel Ray interpreted our recent editorial to mean that we do not endorse vitamin A supplementation among children living in poverty. On the contrary, we are strongly supportive of improving vitamin A status of children but believe that giving capsules to infants is not the only, or necessarily the best, means of doing this. We feel that more attention needs to be paid to improving the vitamin A content of the dietthrough fortification, nutrition education, or food processing -and to supplementing mothers which would have the added benefit of reinforcing crucial messages about the importance of breast feeding. High dose vitamin A capsules, in association with the EPI or otherwise, continue to have a place in public health nutrition but have some drawbacks. Firstly, there are legitimate concerns about the medicalisation of a nutritional problem and the ensuing reliance on drugs imported with foreign currency, rather than on local initiative and technology. Secondly, we maintain that issues of safety of capsules for infants have yet to be satisfactorily addressed. Although available evidence suggests that bulging fontanelle is indeed harmless and should be of little concern to parents,' we consider that the ongoing follow up research on these children into the possibility of prolonged adverse effects is essential. An additional area of concern was suggested in a recent report, namely, that vitamin A dosing at the time of vaccination may decrease the antibody response to measles in a subpopulation of children. We believe this conflict is due to methodological differences, in particular the different time at which samples were taken in other studies. We observed that the detection of increased VPi expression is critically dependent on the timing of the investigation with respect to the onset of disease. Our study suggests that it is not possible to detect the rise in V,2 bearing cells in patients studied early in the disease. A similar finding was observed in Choi et al 's original study of staphylococcal toxic shock syndrome in which peak VP2 expansion was observed 10-14 days after onset of disease.' Choi et al proposed that the timing of sampling explained the inability to detect V,B2 expansion in three of the eight patients studied.
In none of the studies cited by De Inocencio and Hirsch were the results from the acute patients analysed with respect to time after disease onset. In Sakaguchi et al 's study, patients in the 'acute' group (defined as under nine days) may have been studied too early to detect a change in Vr epertoire.
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